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Abstract 
Background and objectives: Contamination risks of propofol 2%, remifentanil, and pantoprazole; 
and in vitro effects of these drugs on the growth of common infective agents in intensive care 
units were evaluated. 
Methods: For detection of contamination risk, drugs were prepared ready to use under 
intensive care unit conditions, were tested. Effects of these three drugs on bacterial growth 
were also investigated. Drugs were prepared at the concentrations used in the intensive care 
unit and inoculated with common pathogens after which they were incubated at 4ºC, 22ºC and 
36ºC. Subcultures were made at 0, 2, 4 and 8 h and colony counts were evaluated. Minimum 
inhibitory concentration values were determined for all drugs at 4ºC, 22ºC and 36ºC.
Results: No growth was observed in the drugs prepared in the intensive care unit. Propofol 
tended to support while remifentanil inhibited bacterial growth. Effect of pantoprozole 
differed according to the bacteria tested. None of the drugs showed antibacterial activity at 
the maximum concentrations which may be achieved in blood of the patients.
Conclusion: Propofol strongly supports the growth of the microorganisms tested, although 
remifentanil and pantoprazole do not. Therefore, it is important to follow the strict aseptic 
techniques for the preparation of propofol.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
Nosocomial infections in the intensive care units (ICU) 
significantly increase morbidity, mortality rates and 
financial cost.1,2 Although, ICUs account for approximately 
10% or less of hospital beds, more than 20% of all nosocomial 
infections occur in patients who are in the ICU.3 Drugs used 
in ICU may influence nosocomial infections by their effect 
on bacterial growth.4 Used ampoules and syringes may be 
contaminated in a busy environment.5,6 There have been 
sporadic reports of bacteremia caused by the distribution 
of infected drugs. Simple infection control protocols are 
shown to be effective in different hospital settings.7,8 Type 
of drug and duration of usage may also be an important 
factor. Knowing the drugs which have a greater tendency 
to create an infection risk, especially the ones used by 
long infusion, would be important for setting up regulations 
and minimizing the risk. Three commonly used drugs in 
critically ill patients and ICU were chosen in this study: 
Propofol, remifentanil and pantoprazole. Propofol is known 
as a good growth medium for bacteria.9 Remifentanil and 
pantoprazole have antibacterial properties.9,10 All these 
drugs are given by long infusions.9,10 Antibacterial effects 
of propofol 1%, remifentanil 1, 10 and 100 μg•mL–1 has 
been studied.4,9 However, the antibacterial effectiveness 
of propofol 2%, remifentanil (40 μg•mL–1) and pantoprazole 
remains to be determined.
The aim of this study was to evaluate the contamination 
risks of propofol 2%, remifentanil, and pantoprazole, and to 
investigate the in vitro effects of these drugs on the growth 
of microorganisms known to be frequent causes of infection 
in intensive care units.
Material and methods
The antimicrobial effect of three anesthetic drugs, propofol 
2% (1.g.50.mL–1 Fresenius Kabi, Germany), remifentanil (2 
mg, GlaxoSmithKline, Italy) and pantoprazole (40 mg, 
Altana Pharma, Germany) were evaluated. All experiments 
were performed in duplicate.
Investigation of contamination risk
All three drugs were prepared for usage in ICU conditions 
according to the protocols used in the ICU to prepare i.v. 
drugs for patients and placed in two separate injectors 
as described.11 As a control, 0.85% NaCl solution was 
also placed in two injectors. One of the injectors was 
incubated at room temperature (22 ± 2ºC) and the other 
in the refrigerator (4 ± 2ºC) in the ICU and 100 μl of the 
incubated drugs were cultured onto Columbia sheep blood 
agar (Becton Dickinson, Germany) at 0, 2, 4 and 8 h. 
Plates were evaluated after overnight incubation at 36 ± 
2ºC. In case of any bacterial growth, colony counts were 
detected. 
Effect on bacterial growth
Bacteria which are frequent causes of nosocomial 
infections and which belong to the normal flora of the 
skin were selected for the study. Staphylococcus aureus 
ATCC 29213, Staphylococcus epidermidis ATCC 12228, 
Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 
25922, Pseudomonas aeruginosa ATCC 27853, and a clinical 
isolate of a multidrug resistant Acinetobacter spp. were 
chosen. 
Effect of drugs at the concentrations  
used in the ICU on bacterial growth
The method used in this part of the study is modified from 
the studies by Batai et al.12 and Wu et al.13 All three drugs 
were prepared for usage in ICU conditions and distributed 
into three sets of sterile tubes, 1 mL per tube. Three sets 
of sterile 0.85% NaCl solution were also prepared. A set 
of tubes consisted of 7 tubes, including all bacteria to be 
tested plus one tube for control. Bacterial solutions were 
prepared at 0.5 MacFarland and diluted by 1/1000.14 All 
tubes except the control tubes were inoculated with 50 
μL of bacterial solutions. No bacteria were added to the 
control tubes. The first set of tubes was incubated at 4 
± 2ºC, the second at 22 ± 2ºC and the third at 36 ± 2ºC. 
The incubated drugs were diluted by 1/100 and 100 μL of 
the dilutions were subcultured onto Columbia sheep blood 
agar at the 0, 2, 4 and 8 h. Plates were evaluated after 
overnight incubation at 36 ± 2ºC. In case of any bacterial 
growth, colony counts were detected.
Determination of minimum inhibitory concentrations  
of drugs
Minimum inhibitory concentration (MIC) values of all 
three drugs and 0.85% NaCl solution were studied by 
microdilution method.14 Microdilution was performed at 
three different temperatures, 4 ± 2ºC, 22 ± 2ºC and 36 
± 2ºC. Cation adjusted Mueller Hinton broth (Oxoid Ltd., 
England) was used for all the bacteria. The concentrations 
to be tested were selected according to the maximum 
concentrations of the drugs in blood of the patients when 
administered.
Statistical analysis
Statistical analysis was carried out using SPSS 11.5 (SPSS 
Inc., Chicago, IL). The one-sample Kolmogorow-Simirnov 
test was used for determining whether the data were 
normally distributed. For colony counts, ANOVA test was 
used to compare four groups of drugs. A t-test on two 
independent samples was used to compare the drug studied 
with normal saline or two different drugs with each other. 
The colony counts at different time points studied was 
analyzed using repeated measures ANOVA. Unless noted 
otherwise, data were presented as mean with standard 
deviation (SD). 
Results
Investigation of contamination risk
In the first part of the study no growth was observed in 
samples prepared ready to use in the ICU and incubated in 
both temperatures.
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Figure 1 The colony counts of Staphylococcus aureus in the solutions tested. a Result is significantly different from the beginning 
(0 h), p < 0.05. b Result is significantly different (p < 0.05) when compared to 0.85% NaCl.
Effect of drugs at the concentrations used  
in the intensive care units on bacterial growth
The mean colony counts of S. aureus, E. faecalis, S. 
epidermidis, E. coli, P. aeruginosa and Acinetobacter spp. 
after exposure to test solutions are shown in Figs. 1 to 6, 
respectively. 
Propofol supported the growth of bacteria. The bacterial 
growth increased or stayed the same for all bacteria at all 
temperatures (Figs. 1-6). Growth of S.aureus in propofol at 
room temperature is shown at Fig. 7.
Remifentanil inhibited bacterial growth and the decrease 
in bacterial counts was more evident at 36 ± 2oC (Figs. 
1-6).
Pantoprazole, did not support bacterial growth and when 
compared to 0th hour, significantly (p < 0.05) reduced the 
bacterial counts of S. epidermidis and Acinetobacter spp. 
in 8 hours at 36 ± 2oC (Figs. 1-6).
Determination of minimum inhibitory concentrations  
of drugs
The MIC values were above the tested concentrations for 
all the drug, microorganism and temperature combinations. 
MICs were > 5 μg•mL–1 for propofol 2%, > 500 μg•mL–1 for 
remifentanil and > 10 mg•mL–1 for pantoprazole.
Discussion
Although propofol is a rich growth medium for bacteria,15 
if propofol was drawn into sterile syringes immediately 
after the ampoules had been opened, no growth was 
detected after 24 hours. Our data are comparable with 
those from other investigations. Warwick et al.16 suggested 
that propofol might be used safely up to 24 hours when 
drawn into sterile syringes. Others have suggested 72 
hours.17 Webb et al. reported contamination of propofol in 
syringes although none caused clinical infection.18 However, 
in our study, colony counts in contaminated syringes 
reached significant difference in 8 hours for S. aureus, E. 
faecalis, E. coli, P. aeruginosa and Acinetobacter spp. at 
36 ± 2oC. Bacterial counts increased in time even at room 
temperature (Fig. 7). Our results were similar with previous 
studies which show that propofol supports the rapid growth 
of E. coli, P. aeruginosa, Enterobacter cloacae, Moraxella 
osloensis, Acinetobacter spp., S. aureus, S. epidermidis, E. 
faecalis and Candida albicans, when inoculated in vitro.19,20 
These findings support the importance of strict aseptic 
techniques. Fluids and drugs may become contaminated 
by microorganisms during production and/or preparation 
for infusion. Poor aseptic technique may be common 
among health care workers especially in a busy work 
environment.21,22 Bacterial contamination of propofol may 
occur during opening of the glass ampoules, and there is 
poor compliance with data sheet recommendations for the 
use of propofol. To escape from bacterial contamination, 
the neck of the ampoule should be wiped with alcohol; 
hands should be washed before any manipulation; syringes 
and pumps should be prepared in aseptic conditions 
immediately before the use of propofol; ampoules and 
syringes should be labeled with the date and hour of 
preparation; propofol should be drawn into syringes in 
amounts that can be used at one time and the residual, if 
any, should be discarded; and finally, disposable devices 
such as syringes, infusion sets and triple manifolds should 
be used for a single patient only.23-25 However, in our 
study, the necks of the ampoules were not wiped with any 
disinfectant to reproduce usual daily working conditions 
but other recommendations were followed. Our results are 
in consistence with the manufacturer’s recommendation 
that propofol should be used within six hours of its handling 
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Figure 2 The colony counts of Enterococcus faecalis in the solutions tested.a Result is significantly different from the beginning 
(0 h), p < 0.05. b Result is significantly different (p < 0.05) when compared to 0.85% NaCl.
and, aseptic techniques should be used in the handling 
and administration of propofol. Even trace contamination 
of propofol is a risk of a significant bacterial load to the 
patient if the drug is not used within the recommended 
time interval.26
On the other hand, temperature had impact on growth 
rates of contaminated propofol. Crowther et al.25 reported 
that the lower temperature may reduce the growth of S. 
aureus. Similarly, our results showed increased growth of 
S. aureus, E. faecalis, E. coli and Acinetobacter spp. at 
higher temperature. However, colony counts increased 
even at 4 ± 2ºC, which pointed out that temperature does 
not guarantee safety in case contamination occurs.
When remifentanil was tested, antimicrobial activity 
was more distinctive for S. aureus and Acinetobacter 
spp.. Strains of E. coli seemed to be more resistant to 
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Figure 3 The colony counts of Staphylococcus epidermidis in the solutions tested. a Result is significantly different from the 
beginning (0 h), p < 0.05. b Result is significantly different (p < 0.05) when compared to 0.85% NaCl.
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antimicrobial effect of remifentanil, supporting Apan 
et al.’s results.9 They reported that the antibacterial 
effect of remifentanil was concentration-dependent. 
The concentrations they used were 1, 10 and 100 
μg•mL–1, where ours was 40 μg•mL–1. The concentration 
of remifentanil we studied was the clinically used 
concentration in our ICU.
Because bacteria are effected by drug pH and most 
pathogenic bacteria prefer a narrow pH range of 6.0-
8.0,25 the bactericidal property of remifentanil might 
be secondary to its low pH. The pH of remifentanil was 
2.1 which is much lower than propofol (pH = 6.35) and 
pantoprozol (pH = 7.68). The growth patterns of S. aureus 
ATCC 25923, E. coli ATCC 25922 or P. aeruginosa ATCC 27853 
Figure 4 The colony counts of Escherichia coli in the solutions tested. a Result is significantly different from the beginning (0 h), 
p < 0.05. 
Figure 5 The colony counts of Pseudomonas aeruginosa in the solutions tested. a Result is significantly different from the beginning 
(0 h), p < 0.05. b Result is significantly different (p < 0.05) when compared to 0.85% NaCl. 
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were not affected by pH between 5.0-8.0.27 In addition, 
remifentanil contains glycine as a preservative which 
increases the duration of antimicrobial activity.28 Presence 
of glycine might contribute to antibacterial activity of 
remifentanil.
Pantoprazole has a widespread use for the treatment of 
a range of upper gastrointestinal diseases in ICU. Suerbaum 
et al.29 reported that pantoprazole has potent in vitro 
antibacterial activity against Helicobacter pylori. The 
mechanism of the antibacterial effect against H. pylori was 
propounded to be the interaction between the bacterial 
proteins via sulfonamide formation. This mechanism might 
be the explanation of pantoprazole’s antibacterial effect 
against S. epidermidis and Acinetobacter spp. in our study, 
however it is yet to be determined.
The main finding of our study is, while remifentanil and 
pantoprazole do not, propofol strongly supports the growth 
of the microorganisms tested. To avoid life threatening 
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Figure 6 The colony counts of Acinetobacter spp. in the solutions tested. a Result is significantly different from the beginning 
(0 h), p < 0.05. b Result is significantly different (p < 0.05) when compared to 0.85% NaCl.
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complications due to bacterial growth in contaminated 
propofol, it is important to follow the strict aseptic 
techniques for the preparation of propofol. Further studies 
should also evaluate the effects of contaminated drugs given 
by infusion on the development of bacteremia in patients. 
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